NR1H4 and metabolic dysfunction-associated steatotic liver disease: In addition, FXR agonists, including synthetic bile acids and steroidal and non-steroidal compounds, have gained interest as potential therapeutic agents for various metabolic disorders, including NAFLD, NASH and T2DM.